ArticleInternational journal of cancer2025
Prediagnostic plasma metabolite concentrations and liver cancer risk: A nested case-control study with long follow-up in the Shanghai Women's Health Study.
Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Present knowledge on metabolic perturbation prior to liver cancer is limited, with most studies unable to quantify the absolute concentrations of metabolites and lacking a focus on female-specific findings. We conducted a 1:1 matched nested case-control study (187 pairs of cases and controls) within the Shanghai Women's Health Study. A targeted metabolomics method was used to quantify 186 metabolites in plasma samples collected at recruitment. A multivariable conditional logistic regression model was utilized to estimate the odds ratio (OR) and 95% confidence interval (CI). Restricted cubic spline function was used to characterize the dose-response associations. A pathway analysis was conducted to identify the most relevant pathways. A metabolic score was calculated via a linear combination of metabolites with nonzero coefficients in the LASSO logistic regression model. After adjustment for potential confounders and correction for multiple testing, 27 metabolites were associated with liver cancer risk and a non-linear association was observed for glutamic acid. Primary bile acid biosynthesis and amino acid biosynthesis and metabolism were important pathways involved in the etiology. A metabolic score derived from 10 metabolites showed a positive linear association with liver cancer risk (OR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.